HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

bivatuzumab mertansine

CD44v6-targeting humanized monoclonal antibody coupled to the toxin mertansine for treatment of squamous cell carcinoma of the head and neck

Also Known As:

BIWI 1 compound

Networked: 4 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Staab, Alexander: 3 articles (04/2007 - 10/2006)
2.	Erhardt, Thomas: 2 articles (09/2008 - 04/2007)
3.	Golze, Wolfram: 2 articles (09/2008 - 04/2007)
4.	Gronau, Silke: 2 articles (09/2008 - 04/2007)
5.	Hanft, Gertraud: 2 articles (09/2008 - 04/2007)
6.	Hoermann, Karl: 2 articles (09/2008 - 04/2007)
7.	Riechelmann, Herbert: 2 articles (09/2008 - 04/2007)
8.	Sauter, Alexander: 2 articles (09/2008 - 04/2007)
9.	Schroen, Carsten: 2 articles (09/2008 - 04/2007)
10.	Bogeschdorfer, Felix: 1 article (04/2007)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 04/01/2007 - "The purpose of this study was to investigate the safety, pharmacokinetics and preliminary efficacy of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer. " 04/01/2007 - "Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study." 04/01/2007 - "In conclusion, bivatuzumab mertansine targets CD44v6 and appears to stabilize heavily pretreated metastatic breast cancer that expresses CD44v6. " 04/01/2007 - "Anthracycline and taxane-pretreated patients with metastatic breast cancer that expressed CD44v6 received one single infusion of bivatuzumab mertansine and were observed for 21 days within one treatment course. "
2.	Squamous Cell Carcinoma of Head and Neck 10/15/2006 - "A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus." 09/01/2008 - "Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma." 04/01/2007 - "Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck."
3.	Stevens-Johnson Syndrome (Lyell's Syndrome) 04/01/2007 - "As a consequence of one fatal toxic epidermal necrolysis that occurred in a study running in parallel, the clinical trials programme of bivatuzumab mertansine was discontinued. "

Related Drugs and Biologics

1.	Immunoconjugates (Immunoconjugate)
2.	Anthracyclines
3.	taxane